These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1398 related articles for article (PubMed ID: 28980624)

  • 21. Transcranial direct current stimulation does not modulate motor cortex excitability in patients with amyotrophic lateral sclerosis.
    Munneke MA; Stegeman DF; Hengeveld YA; Rongen JJ; Schelhaas HJ; Zwarts MJ
    Muscle Nerve; 2011 Jul; 44(1):109-14. PubMed ID: 21674525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders.
    Goutman SA
    Continuum (Minneap Minn); 2017 Oct; 23(5, Peripheral Nerve and Motor Neuron Disorders):1332-1359. PubMed ID: 28968365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of amyotrophic lateral sclerosis.
    Bali T; Miller TM
    Mo Med; 2013; 110(5):417-21. PubMed ID: 24279194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organophosphate neurotoxicity to the voluntary motor system on the trail of environment-caused amyotrophic lateral sclerosis: the known, the misknown, and the unknown.
    Merwin SJ; Obis T; Nunez Y; Re DB
    Arch Toxicol; 2017 Aug; 91(8):2939-2952. PubMed ID: 28070599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revisiting the concept of amyotrophic lateral sclerosis as a multisystems disorder of limited phenotypic expression.
    Strong MJ
    Curr Opin Neurol; 2017 Dec; 30(6):599-607. PubMed ID: 28914734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical practice guideline for the management of amyotrophic lateral sclerosis in Japan-update 2023.
    Urushitani M; Warita H; Atsuta N; Izumi Y; Kano O; Shimizu T; Nakayama Y; Narita Y; Nodera H; Fujita T; Mizoguchi K; Morita M; Aoki M
    Rinsho Shinkeigaku; 2024 Apr; 64(4):252-271. PubMed ID: 38522911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyotrophic lateral sclerosis.
    Kiernan MC; Vucic S; Cheah BC; Turner MR; Eisen A; Hardiman O; Burrell JR; Zoing MC
    Lancet; 2011 Mar; 377(9769):942-55. PubMed ID: 21296405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis.
    Körner S; Kollewe K; Fahlbusch M; Zapf A; Dengler R; Krampfl K; Petri S
    Muscle Nerve; 2011 May; 43(5):636-42. PubMed ID: 21484822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation and rehabilitation of patients with adult motor neuron disease.
    Francis K; Bach JR; DeLisa JA
    Arch Phys Med Rehabil; 1999 Aug; 80(8):951-63. PubMed ID: 10453774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 'Omics' of Amyotrophic Lateral Sclerosis.
    Caballero-Hernandez D; Toscano MG; Cejudo-Guillen M; Garcia-Martin ML; Lopez S; Franco JM; Quintana FJ; Roodveldt C; Pozo D
    Trends Mol Med; 2016 Jan; 22(1):53-67. PubMed ID: 26691296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary management of the ALS patient.
    Tidwell J
    J Neurosci Nurs; 1993 Dec; 25(6):337-42. PubMed ID: 8106826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyotrophic Lateral Sclerosis and the Respiratory System.
    Braun AT; Caballero-Eraso C; Lechtzin N
    Clin Chest Med; 2018 Jun; 39(2):391-400. PubMed ID: 29779597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The causes and mechanism of selective motor neuron death in amyotrophic lateral sclerosis].
    Van den Bosch L
    Verh K Acad Geneeskd Belg; 2006; 68(4):249-69. PubMed ID: 17214440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in amyotrophic lateral sclerosis.
    Al-Chalabi A; Leigh PN
    Curr Opin Neurol; 2000 Aug; 13(4):397-405. PubMed ID: 10970056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical aspects of amyotrophic lateral sclerosis].
    Zeitlhofer J
    Wien Med Wochenschr; 1996; 146(9-10):182-5. PubMed ID: 9012207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of motor neuron restorative therapy in amyotrophic lateral sclerosis using hepatocyte growth factor].
    Aoki M; Warita H; Suzuki N; Itoyama Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):814-7. PubMed ID: 20030218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consideration of gravity as a possible etiological factor in amyotrophic lateral sclerosis.
    Akaishi T; Takahashi T; Abe M; Aoki M; Ishii T
    Med Hypotheses; 2019 Nov; 132():109369. PubMed ID: 31442918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
    Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
    J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple orofacial indices in amyotrophic lateral sclerosis.
    DePaul R; Brooks BR
    J Speech Hear Res; 1993 Dec; 36(6):1158-67. PubMed ID: 8114482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis.
    Duffy LM; Chapman AL; Shaw PJ; Grierson AJ
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):336-52. PubMed ID: 21299590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.